Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07065942

Effects of Lactulose on Gut Microbiota and Metabolism in Diabetic Constipated Patients

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Peking Union Medical College Hospital · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Constipation is the most common gastrointestinal manifestation in diabetic patients. Emerging evidence suggests that gut microbiota dysbiosis may contribute to the pathogenesis of diabetes, highlighting the need to investigate its role in diabetic constipation, though current research remains limited. Current management of diabetic constipation primarily relies on bulk-forming and osmotic laxatives. Additionally, microbiome-modulating agents (e.g., probiotics, prebiotics, and synbiotics) may serve as adjunctive therapies by regulating gut microbiota and enhancing intestinal motility. Lactulose, a well-tolerated osmotic laxative with prebiotic effects, is widely recommended in clinical guidelines. It promotes short-chain fatty acid production, increases fecal volume, and accelerates colonic transit, thereby alleviating constipation. However, its specific impact on gut microbiota composition and metabolic pathways in diabetic constipation remains unclear. This study aims to explore changes in fecal microbiota and metabolomic profiles in diabetic patients with chronic constipation following treatment with lactulose alone or in combination with Bacillus subtilis-Enterococcus faecium probiotics, providing mechanistic insights into prebiotic therapy for this condition.

Conditions

Interventions

TypeNameDescription
DRUGLactulose oral solutionOral, 30 mL once daily administered during breakfast.
DRUGLive Combined B. Subtilis and E. Faecium Enteric-coated CapsulesOral, 2 tablets (500 mg per tablet) three times daily (TID).

Timeline

Start date
2023-07-01
Primary completion
2026-07-30
Completion
2026-07-30
First posted
2025-07-15
Last updated
2025-07-15

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07065942. Inclusion in this directory is not an endorsement.